Login to Your Account

Jenrin on ‘Peripherally Selective’ Path to Treat Diabetes

By Marie Powers
Staff Writer

Friday, September 13, 2013

Virtual biotech Jenrin Discovery LLC spent its first six years targeting peripherally selective (PS) CB1 receptor antagonists as a safer and more effective approach to treat diabetes and other metabolic disorders.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription